Children with infantile spasms are likely to have a poor outcome. Outcome measures for
infantile spasms include primary response to treatment, relapse of spasms, neurological …

PURPOSE: The goal of this retrospective study is to review the causes of infantile spasms
and to correlate aetiology with outcome. METHODS: All children diagnosed with infantile …

The following aspects are reviewed: Does the aetiology influence the outcome of infantile
spasms? Does the treatment influence the outcome? Can the outcome be predicted? Can …

Summary Purpose: Prior to the United Kingdom Infantile Spasms Study (UKISS), our
practice was to initiate vigabatrin for infantile spasms. However, since then we tend to use …

The treatment of infantile spasms is challenging, especially in the context of the following:(1)
a severe phenotype with high morbidity and mortality;(2) the urgency of diagnosis and …

Objective: To determine the current best practice for treatment of infantile spasms in children.
Methods: Database searches of MEDLINE from 1966 and EMBASE from 1980 and searches …

Purpose: The efficacy of a protocol consisting of vigabatrin (VGB) as the first and
adrenocorticotropic hormone (ACTH) or valproate (VPA) as the second drug was studied in …

Objective Evaluation of efficacy of vigabatrin as the first drug in infants with previously
untreated infantile spasms (IS) and reporting the long‐term outcome. Methods We analyzed …

Purpose: The efficacy and tolerability of vigabatrin (VGB) as an add‐on therapy in the
treatment of infantile spasm (IS) prompted physicians to explore its use as the first drug in …

Objective Infantile spasms (IS) represent a severe epileptic encephalopathy presenting in
the first 2 years of life. Recommended first‐line therapies (hormonal therapy or vigabatrin) …